Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
02/2003
02/11/2003US6518300 Antiplipemic agent, anticholesterol agents
02/11/2003US6518292 Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
02/11/2003US6518290 Substituted oxazoles and thiazoles derivatives as HPPAr alpha activators
02/11/2003US6518287 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
02/11/2003US6518286 Compounds
02/11/2003US6518277 Disrupting leukocyte function
02/11/2003US6518267 Protease inhibitors
02/11/2003US6518264 For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders
02/11/2003US6518239 Dry powder compositions having improved dispersivity
02/11/2003US6518238 Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
02/11/2003US6517883 Satiety product
02/11/2003US6517866 Sertraline salts and sustained-release dosage forms of sertraline
02/11/2003US6517862 Containing trace elements
02/11/2003CA2174529C Dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) and uses thereof
02/11/2003CA2151564C Monomeric insulin analog formulations
02/11/2003CA2125476C 20-methyl-substituted vitamin d derivatives
02/11/2003CA2041818C Separation of enantiomers of cimaterol, (-)-cimaterol and the use thereof as pharmaceutical compositions or as performance enhancers
02/10/2003WO2002014320A2 Novel substituted diaryl azepine derivatives as integrin ligands
02/10/2003CA2419078A1 Substituted diaryl azepine derivatives as integrin ligands
02/07/2003CA2354743A1 Mitochondrially targeted antioxidants
02/06/2003WO2003010315A1 Abca7 splicing variant
02/06/2003WO2003010314A2 Gmg-2 polynucleotides and polypeptides and uses thereof
02/06/2003WO2003010303A1 Methods of inducing differentiation of stem cells
02/06/2003WO2003010298A1 'probiotic lactobacillus salivarius strains
02/06/2003WO2003010297A1 Probiotic bifidobacterium strains
02/06/2003WO2003010286A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
02/06/2003WO2003010281A2 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
02/06/2003WO2003010173A1 Stabilized derivatives of ascorbic acid -3-phosphate
02/06/2003WO2003010168A1 4-oxoimidazolidine-2-spiropiperidine derivative
02/06/2003WO2003010159A1 Piperidine derivatives as nmda receptor antagonists
02/06/2003WO2003010147A1 Acidic quinolone derivatives
02/06/2003WO2003010139A2 Antisense modulation of hormone-sensitive lipase expression
02/06/2003WO2003010135A1 Novel phenylpropionic acid derivatives
02/06/2003WO2003010129A1 Process for the preparation of (r)- or (s)-aminocarnitine inner salt, the salts and derivatives thereof
02/06/2003WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
02/06/2003WO2003009865A1 Agonists and antagonists of energen for use in the treatment of metabolic disorders
02/06/2003WO2003009864A1 Agonists and antagonists of disomet for the treatment of metabolic disorders
02/06/2003WO2003009863A1 Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
02/06/2003WO2003009862A1 Agonists and antagonists of modumet for use in the treatment of metabolic disorders
02/06/2003WO2003009861A1 Agonists and antagonists of metabolix in the treatment of metabolic disorders
02/06/2003WO2003009854A1 Lipid lowering composition comprising carnitine and phytosterol
02/06/2003WO2003009853A1 Methods for preventing antipsychotic-induced weight gain
02/06/2003WO2003009847A1 Substituted piperidines as modulators of the melanocortin receptor
02/06/2003WO2003009845A1 Substituted urea neuropeptide y y5 receptor antagonists
02/06/2003WO2003009841A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
02/06/2003WO2003009840A1 Composition comprising at least one lipase inhibitor and carnitine
02/06/2003WO2003009838A1 Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
02/06/2003WO2003009828A1 Modifying the fatty acid composition of cell membranes of organs and tissues
02/06/2003WO2003009813A2 Methods of treating neuropilin-mediated diseases
02/06/2003WO2003009807A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
02/06/2003WO2003009779A2 Delivery of therapeutic capable agents
02/06/2003WO2003009778A2 Methods and devices for delivery of therapeutic capable agents with variable release profile
02/06/2003WO2003009777A2 Delivery of therapeutic capable agents
02/06/2003WO2003009741A2 Methods for treating joint inflammation, pain, and loss of mobility
02/06/2003WO2002095034A3 A retinoic acid metabolizing cytochrome p450
02/06/2003WO2002092772A3 Antisense modulation of ptp1b expression
02/06/2003WO2002087556A3 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
02/06/2003WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
02/06/2003WO2002069689A3 Gssp4 polynucleotides and polypeptides and uses thereof
02/06/2003WO2002067851A3 Method for treating fibrotic diseases or other indications iiic
02/06/2003WO2002066418A3 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor
02/06/2003WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof
02/06/2003WO2002063005A3 Lipid-associated molecules
02/06/2003WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors
02/06/2003WO2002048134A3 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
02/06/2003WO2002046172A3 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
02/06/2003WO2002046141A3 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis
02/06/2003WO2002041843A3 Antiinflammation agents
02/06/2003WO2002020722A3 Methods and compositions for in vitro targeting
02/06/2003WO2002010137A9 Indazole derivatives as jnk inhibitors
02/06/2003WO2002002645A8 COLD WATER SOLUBLE β-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME
02/06/2003WO2001047946A3 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR
02/06/2003US20030028923 Nucleotide sequences coding enzymatic polypeptide for use in the generation of disease resistant plants
02/06/2003US20030028910 Animal model for use in the diagnosis and treatment dietetics
02/06/2003US20030028089 Diabetes management system
02/06/2003US20030027859 3-aryl-2-hydroxypropionic acid derivative I
02/06/2003US20030027851 Readily soluble crystal modification; specific X-ray diffraction pattern obtained with a focusing Debye-Scherrer beam and Cu-K alpha 1-radiation
02/06/2003US20030027845 Ether derivatives useful as inhibitors of PDE4 isozymes
02/06/2003US20030027840 Estrogen receptor modulators
02/06/2003US20030027836 Arylalkoxy-substituted tetrahydroisoquinoline-3-carboxylic acids or esters
02/06/2003US20030027831 Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases
02/06/2003US20030027821 Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder
02/06/2003US20030027820 Method for treating fibrotic diseases or other indications V
02/06/2003US20030027812 Useful for treating or preventing a disorder or condition selected from hypertension, depression, anxiety, phobias, post trauma stress, sexual disfunction, eating disorder, obesity, Alzheimer's disease, Parkinson's disease etc.
02/06/2003US20030027804 Administering to the mammal a menopause disorder effective amount of an orally deliverable pharmaceutically- acceptable sex hormone binding globulin synthesis inhibiting agent, and at least one of a non-orally deliverable steroids
02/06/2003US20030027802 Methods for preventing antipsychotic-induced weight gain
02/06/2003US20030027797 For therapy of metabolic disorders related to insulin resistance or hyperglycemia
02/06/2003US20030027795 N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
02/06/2003US20030027794 N-heterocyclic derivatives as NOS inhibitors
02/06/2003US20030027786 Lipase inhibiting composition
02/06/2003US20030027759 Method of using PON-1 to decrease atheroma formation
02/06/2003US20030027748 For therapy of diabetes
02/06/2003US20030027743 Tripeptidylpeptidase inhibitors
02/06/2003US20030027337 Sequence-specific DNA recombination in eukaryotic cells
02/06/2003US20030027297 19 human secreted proteins
02/06/2003US20030027261 Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof
02/06/2003US20030027253 Nucleotides equences codin polypeptide for use in the treatment of cancer
02/06/2003US20030027211 Fetuin-MGP-mineral complex in serum
02/06/2003US20030027164 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
02/06/2003US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides
1 ... 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 ... 1298